Home » Stocks » Halozyme Therapeutics

Halozyme Therapeutics, Inc. (HALO)

Stock Price: $27.19 USD -0.31 (-1.13%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 3.69B
Revenue (ttm) 164.40M
Net Income (ttm) -80.14M
Shares Out 135.82M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE 29.85
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $27.19
Previous Close $27.50
Change ($) -0.31
Change (%) -1.13%
Day's Open 27.51
Day's Range 26.67 - 27.55
Day's Volume 552,702
52-Week Range 12.71 - 29.34

More Stats

Market Cap 3.69B
Enterprise Value 3.71B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 135.82M
Float 126.81M
EPS (basic) -0.55
EPS (diluted) -0.56
FCF / Share -0.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 16.35M
Short Ratio 11.38
Short % of Float 13.85%
Beta 1.83
PE Ratio n/a
Forward PE 29.85
P/FCF Ratio n/a
PS Ratio 22.46
PB Ratio 64.35
Revenue 164.40M
Operating Income -73.80M
Net Income -80.14M
Free Cash Flow -88.33M
Net Cash -20.75M
Net Cash / Share -0.15
Gross Margin 16.33%
Operating Margin -44.89%
Profit Margin -48.70%
FCF Margin -53.73%
ROA -6.16%
ROE -50.39%
ROIC -12.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 8
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$30.00*
(10.33% upside)
Low
13.0
Current: $27.19
High
39.0
Target: 30.00
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue19615231714713575.3354.8042.3356.0913.62
Revenue Growth29.06%-52.04%115.84%8.61%79.28%37.47%29.47%-24.54%311.67%-
Gross Profit15014228511310652.6048.5541.2355.8312.64
Operating Income-67.61-69.3381.00-83.21-27.45-63.04-80.43-53.63-19.84-54.26
Net Income-72.24-80.3362.97-103-32.23-68.38-83.48-53.55-19.77-53.24
Shares Outstanding14414413612812712311311110394.36
Earnings Per Share-0.50-0.560.45-0.81-0.25-0.56-0.74-0.48-0.19-0.56
Operating Cash Flow-85.42-49.50134-50.38-37.08-47.52-49.34-64.28-34.30-45.39
Capital Expenditures-4.04-4.66-1.35-3.14-2.36-1.37-2.30-1.41-0.83-0.65
Free Cash Flow-89.46-54.16133-53.52-39.44-48.89-51.64-65.69-35.13-46.03
Cash & Equivalents42235547020510913672.0099.9052.8383.26
Total Debt40312620221749.8349.8649.7731.11--
Net Cash / Debt19.18229267-11.1459.0186.2622.2368.7952.8383.26
Assets56644052026218216610213565.7691.35
Liabilities47419131229413912512285.8754.8670.99
Book Value91.77249208-32.4843.0041.35-19.9948.8510.9020.35
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Halozyme Therapeutics, Inc.
Country United States
Employees 132
CEO Helen I. Torley

Stock Information

Ticker Symbol HALO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HALO

Description

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.